187 related articles for article (PubMed ID: 28651973)
1. 1,25(OH)
Abu El Maaty MA; Alborzinia H; Khan SJ; Büttner M; Wölfl S
Biochim Biophys Acta Mol Cell Res; 2017 Oct; 1864(10):1618-1630. PubMed ID: 28651973
[TBL] [Abstract][Full Text] [Related]
2. Activation of pro-survival metabolic networks by 1,25(OH)
Abu El Maaty MA; Dabiri Y; Almouhanna F; Blagojevic B; Theobald J; Büttner M; Wölfl S
Cancer Metab; 2018; 6():11. PubMed ID: 30181873
[TBL] [Abstract][Full Text] [Related]
3. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1999 Mar; 140(3):1205-12. PubMed ID: 10067845
[TBL] [Abstract][Full Text] [Related]
4. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
Ikezoe T; Gery S; Yin D; O'Kelly J; Binderup L; Lemp N; Taguchi H; Koeffler HP
Cancer Res; 2005 Jun; 65(11):4762-8. PubMed ID: 15930295
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D and testosterone co-ordinately modulate intracellular zinc levels and energy metabolism in prostate cancer cells.
Zhang P; Schatz A; Adeyemi B; Kozminski D; Welsh J; Tenniswood M; Wang WW
J Steroid Biochem Mol Biol; 2019 May; 189():248-258. PubMed ID: 30664926
[TBL] [Abstract][Full Text] [Related]
7. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
8. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
9. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth.
Gavrilov V; Steiner M; Shany S
Anticancer Res; 2005; 25(5):3425-9. PubMed ID: 16101159
[TBL] [Abstract][Full Text] [Related]
10. GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells.
Flores O; Burnstein KL
Endocrinology; 2010 Oct; 151(10):4654-64. PubMed ID: 20739400
[TBL] [Abstract][Full Text] [Related]
11. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
12. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays.
Krishnan AV; Shinghal R; Raghavachari N; Brooks JD; Peehl DM; Feldman D
Prostate; 2004 May; 59(3):243-51. PubMed ID: 15042599
[TBL] [Abstract][Full Text] [Related]
13. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
14. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
15. Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile.
Vaz CV; Alves MG; Marques R; Moreira PI; Oliveira PF; Maia CJ; Socorro S
Int J Biochem Cell Biol; 2012 Nov; 44(11):2077-84. PubMed ID: 22964025
[TBL] [Abstract][Full Text] [Related]
16. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity.
Swami S; Krishnan AV; Peehl DM; Feldman D
Mol Cell Endocrinol; 2005 Sep; 241(1-2):49-61. PubMed ID: 15955619
[TBL] [Abstract][Full Text] [Related]
17. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells.
Rohan JN; Weigel NL
Endocrinology; 2009 May; 150(5):2046-54. PubMed ID: 19164469
[TBL] [Abstract][Full Text] [Related]
18. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.
Hedlund TE; Moffatt KA; Miller GJ
Endocrinology; 1996 May; 137(5):1554-61. PubMed ID: 8612485
[TBL] [Abstract][Full Text] [Related]
19. The role of vitamin D in prostate cancer.
Krishnan AV; Peehl DM; Feldman D
Recent Results Cancer Res; 2003; 164():205-21. PubMed ID: 12899524
[TBL] [Abstract][Full Text] [Related]
20. The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells.
Myrthue A; Rademacher BL; Pittsenbarger J; Kutyba-Brooks B; Gantner M; Qian DZ; Beer TM
Clin Cancer Res; 2008 Jun; 14(11):3562-70. PubMed ID: 18519790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
